Cancer Research Meeting Calendar  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cartee, L.
Right arrow Articles by Grant, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cartee, L.
Right arrow Articles by Grant, S.
[Cancer Research 61, 2583-2591, March 15, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

The Cyclin-dependent Kinase Inhibitor (CDKI) Flavopiridol Disrupts Phorbol 12-Myristate 13-Acetate-induced Differentiation and CDKI Expression while Enhancing Apoptosis in Human Myeloid Leukemia Cells1

Leanne Cartee, Zhiliang Wang, Roy H. Decker, Srikumar P. Chellappan, Gina Fusaro, Karen G. Hirsch, Heidi M. Sankala, Paul Dent and Steven Grant2

Departments of Medicine [L. C., Z. W., K. G. H., S. G.], Pharmacology and Toxicology [S. G.], Biochemistry [R. H. D.], Radiation Oncology [H. M. S., P. D.], and Microbiology [S. G.], Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia 23298, and the Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10021 [G. F., S. P. C.]

Interactions between the cyclin-dependent kinase inhibitor (CDKI) flavopiridol (FP) and phorbol 12-myristate 13-acetate (PMA) were examined in U937 human leukemia cells in relation to differentiation and apoptosis. Simultaneous, but not sequential, exposure of U937 cells to 100 nM FP and 10 nM PMA significantly increased apoptosis manifested by characteristic morphological features, mitochondrial dysfunction, caspase activation, and poly(ADP-ribose) polymerase cleavage while markedly inhibiting cellular differentiation, as reflected by diminished plastic adherence and CD11b expression. Enhanced apoptosis in U937 cells was associated with an early caspase-independent increase in cytochrome c release and accompanied by a substantial decline in leukemic cell clonogenicity. Moreover, PMA/FP cotreatment significantly increased apoptosis in HL-60 promyelocytic leukemia cells and in U937 cells ectopically expressing the Bcl-2 protein. In U937 cells, coadministration of FP blocked PMA-induced expression and reporter activity of the CDKI p21WAF1/CIP1 and triggered caspase-mediated cleavage of the CDKI p27KIP1. Coexposure to FP also resulted in a more pronounced and sustained activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinase cascade after PMA treatment, although disruption of this pathway by the mitogen-activated protein kinase kinase 1 inhibitor U0126 did not prevent potentiation of apoptosis. FP accelerated PMA-mediated dephosphorylation of the retinoblastoma protein (pRb), an event followed by pRb cleavage culminating in the complete loss of underphosphorylated pRb ({approx}Mr 110,000) by 24 h. Finally, gel shift analysis revealed that coadministration of FP with PMA for 8 h led to diminished E2F/pRb binding compared to the effects of PMA alone. Collectively, these findings indicate that FP modulates the expression/activity of multiple signaling and cell cycle regulatory proteins in PMA-treated leukemia cells and that such alterations are associated with mitochondrial damage and apoptosis rather than maturation. These observations also raise the possibility that combining CDKIs and differentiation-inducing agents may represent a novel antileukemic strategy.




This article has been cited by other articles:


Home page
BloodHome page
S.-R. A. Hussain, D. M. Lucas, A. J. Johnson, T. S. Lin, A. P. Bakaletz, V. X. Dang, S. Viatchenko-Karpinski, A. S. Ruppert, J. C. Byrd, P. Kuppusamy, et al.
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Blood, March 15, 2008; 111(6): 3190 - 3199.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. K. Schwartz and M. A. Shah
Targeting the Cell Cycle: A New Approach to Cancer Therapy
J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. K. Schwartz
Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K.-W. Zhao, X. Li, Q. Zhao, Y. Huang, D. Li, Z.-G. Peng, W.-Z. Shen, J. Zhao, Q. Zhou, Z. Chen, et al.
Protein kinase C{delta} mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation
Blood, December 1, 2004; 104(12): 3731 - 3738.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. L. Schneider and M. Kulesz-Martin
Destructive cycles: the role of genomic instability and adaptation in carcinogenesis
Carcinogenesis, November 1, 2004; 25(11): 2033 - 2044.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res., May 15, 2004; 64(10): 3653 - 3660.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. R. Rosato, J. A. Almenara, C. Yu, and S. Grant
Evidence of a Functional Role for p21WAF1/CIP1 Down-Regulation in Synergistic Antileukemic Interactions between the Histone Deacetylase Inhibitor Sodium Butyrate and Flavopiridol
Mol. Pharmacol., March 1, 2004; 65(3): 571 - 581.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. M. Nguyen, W. D. Schrump, G. A. Chen, W. Tsai, P. Nguyen, J. B. Trepel, and D. S. Schrump
Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells
Clin. Cancer Res., March 1, 2004; 10(5): 1813 - 1825.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, Y. Dai, and S. Grant
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells
Mol. Cancer Ther., December 1, 2003; 2(12): 1273 - 1284.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Jiang, C. B. Matranga, D. Cai, V. M. Latham Jr., X. Zhang, A. M. Lowell, F. Martelli, and G. I. Shapiro
Flavopiridol-Induced Apoptosis during S Phase Requires E2F-1 and Inhibition of Cyclin A-Dependent Kinase Activity
Cancer Res., November 1, 2003; 63(21): 7410 - 7422.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. M. Nguyen, W. D. Schrump, W. S. Tsai, A. Chen, J. H. Stewart IV, F. Steiner, and D. S. Schrump
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling pathway
J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1132 - 1142.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Cartee, S. C. Maggio, R. Smith, H. M. Sankala, P. Dent, and S. Grant
Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol
Mol. Cancer Ther., January 1, 2003; 2(1): 83 - 93.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Gojo, B. Zhang, and R. G. Fenton
The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1
Clin. Cancer Res., November 1, 2002; 8(11): 3527 - 3538.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. Cartee, R. Smith, Y. Dai, M. Rahmani, R. Rosato, J. Almenara, P. Dent, and S. Grant
Synergistic Induction of Apoptosis in Human Myeloid Leukemia Cells by Phorbol 12-Myristate 13-Acetate and Flavopiridol Proceeds via Activation of Both the Intrinsic and Tumor Necrosis Factor-Mediated Extrinsic Cell Death Pathways
Mol. Pharmacol., June 1, 2002; 61(6): 1313 - 1321.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, L. Cartee, V. Betts, S. P. Chellappan, and S. Grant
The Cyclin-dependent Kinase Inhibitor Flavopiridol Disrupts Sodium Butyrate-induced p21WAF1/CIP1 Expression and Maturation while Reciprocally Potentiating Apoptosis in Human Leukemia Cells
Mol. Cancer Ther., February 1, 2002; 1(4): 253 - 266.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. A. Shah and G. K. Schwartz
Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy
Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.